Epidemiology, species distribution and outcome of nosocomial *Candida* spp. bloodstream infection in Shanghai — A retrospective of 11-year clinical analysis in a shanghai tertiary hospital

yanjun Zheng

Shanghai Jiao Tong University Medical School Affiliated Ruijin Hospital

xie Ting

Suining Central Hospital

lin Wu

Shanghai Jiao Tong University Medical School Affiliated Ruijin Hospital

xiaoying Liu

Shanghai Jiao Tong University Medical School Affiliated Ruijin Hospital

ling Zhu

ruijin north hospital

ying Chen

Shanghai Jiao Tong University Medical School Affiliated Ruijin Hospital

enqiang Mao

Shanghai Jiao Tong University Medical School Affiliated Ruijin Hospital

erzhen Chen

Shanghai Jiao Tong University Medical School Affiliated Ruijin Hospital

zhitao Yang (✉ yangzhitao@hotmail.fr)

Shanghai Jiao Tong University Medical School Affiliated Ruijin Hospital <https://orcid.org/0000-0002-6289-6493>

Research article

Keywords: *Candida* spp; Bloodstream infection; Epidemiology; Species distribution; Antifungal therapy; Susceptibility; Early treatment; Survival

Posted Date: February 27th, 2020

DOI: <https://doi.org/10.21203/rs.2.24729/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License. [Read Full License](#)

Abstract

Background: *Candida* spp. are important opportunist pathogens causing bloodstream infections (BSIs). The present study aims to describe the current epidemiology of *Candida* BSI in a large Shanghai Tertiary-care Hospital from 2008 to 2018, and to identify the risk factors and the impact of antifungal therapy on clinical outcome.

Methods: From January 2008 to December 2018, all consecutive patients who developed *Candida* BSI at Ruijin Hospital were enrolled. Underlying diseases, clinical severity, species distribution, antifungal therapy and its impact on the outcome were analyzed.

Results: The incidence of nosocomial *Candida* BSI was 0.39 episodes/1000 hospitalized patients, and overall 30-day mortality rate was 28.5%. Among the 393 cases of *Candida* BSI, 299 cases (76.1%) received antifungal therapy. 247 received appropriate antifungal therapy, and 52 received delayed antifungal therapy (5 days after onset of *Candida* BSI). The 30-day mortality rate was significantly lower in those who received appropriate antifungal therapy or delayed antifungal therapy compared with those who did not receive antifungal therapy (25.5% and 23.1% vs. 39.4% $P=0.012$ and $P=0.046$). In multivariate Cox regression analysis, age, chronic renal failure, mechanical ventilation, neutropenia were independent risk factors for the 30-day mortality rate, while antifungal therapy was a protective factor for short-term survival rate.

Conclusion: The epidemiology of *Candida* BSI in Shanghai differed from that observed in Western countries. Antifungal therapy did influence the short-term survival, while there was no significant difference between the mortality for those who received appropriate antifungal therapy and for those who received delayed antifungal therapy.

Background

The incidence of invasive fungal infection has increased over time, especially for *Candida* bloodstream infections (BSIs), which was associated with considerable excess mortality and costs. In the past two decades, the incidence of fungal infection has increased from 0.1 episodes/1000 admissions to 0.3–0.6 episodes/1000 admissions in China, North America and some European countries[1–4]. The mortality rate was as high as 47.9%[5]. The lack of specific clinical manifestations, rapid and sensitive diagnostic tests has led to the fact that patients were hard to get access to early diagnosis and treatment. The overuse of antifungal agent results in increased costs, selection pressure for resistance and adverse drug interactions, etc. Several studies showed that delayed antifungal therapy (more than 48 h from onset) was associated with higher mortality[6], while others have yielded conflicting results[7–9].

In this study, we retrospectively analyzed all *Candida* bloodstream infection patients from 2008 to 2018 in our hospital, aiming to describe their clinical characteristics, species distribution, antifungal therapy and to identify its risk factors for 30-day mortality.

Methods

Study Setting and population

A retrospective analysis of consecutive *Candida* bloodstream episodes in adults collected from the microbiology database of a 1900-bed teaching hospital in Shanghai, was performed over a 11-year period (from 1st January 2008 to 31st December 2018).

Demographics, underlying diseases, co-morbidities, severity of clinical features, *Candida* species distribution, prior antibiotic use and appropriate or delayed antifungal treatment were compared among the patients with *Candida* BSI. The initial and target antifungal agent use was also collected.

A case of *Candida* BSI was defined as a patient with at least one blood culture positive for a *Candida*. Two or more blood cultures positive to different *Candida* within 14 days were considered one episode of *Candida* BSI[10]. Neutropenia was defined as $<500/\text{mm}^3$ absolute neutrophil count. Prior corticosteroid was defined as receiving >1 mg/kg/d prednisone for more than one week or equivalent before *Candida* BSI onset. Antibiotic treatment was considered if the patient has been on antibiotic treatment prior to *Candida* BSI, for at least 3 days.

Laboratory Methods

Isolates were detected from blood cultures using the BACTEC™ FX system (Becton Dickinson, Inc., Sparks, MD, USA). Flucytosine, amphotericin B, fluconazole, voriconazole, and itraconazole susceptibility testings were performed using the ATB® FUNGUS 3 system (BioMérieux, France), which was widely used in China[11], providing susceptibility to antifungals results markedly concordant with those obtained using CLSI and EUCAST methodologies[12].

Initial appropriate antifungal treatment was considered when the appropriate drug (based on subsequent in vitro susceptibility results) with adequate dosage was started within 5 days the first blood culture performed[13]. Adequate dosage of antifungal agent was defined according

to IDSA 2009 guidelines or 2016 IDSA[10, 14]. Delayed antifungal treatment was defined when appropriate target treatment started after 5 days of BSI onset based on susceptibility results, regardless of whether inappropriate antifungal treatment has been initiated or not. Crude mortality was registered after 30 days from the occurrence of Candida BSI.

Statistical analysis

Descriptive analyses were used for baseline characteristics and subgroup analyses. Continuous variables were expressed as means $\pm$ SD. The Chi-square-test or 2-tailed Fisher Exact-test was used to compare categorical variables. To define risk factors for mortality, multivariate Cox regression analysis and adjusted odds ratio (OR) with 95% confidence interval (CI) were calculated. Variables that were associated with 30-day mortality in Cox univariate analyses with a $P < 0.05$ were entered into multivariate analysis. 2-tailed tests of significance at the level of a P value of < 0.05 level was used to determine statistical significance. Statistical analysis has been conducted by using the program SPSS 22.0.

Ethics

The study was approved by the local institutional review board (Ruijin Hospital, Shanghai Jiaotong University, School of medicine) and written patient consent was not required because of the observational nature of this study.

Results

Incidence and demographic characteristics of patients

A total of 393 consecutive episodes of *Candida* BSI were collected, occurred in 370 inpatients, during an 11-year study period with an incidence of 0.39 episodes/1000 admissions, which has increased steadily, as shown in Figure 1. (0.21 episodes per 1,000 admissions in 2008, 0.24 in 2009, 0.26 in 2010, 0.44 in 2011, 0.42 in 2012, 0.37 in 2013, 0.40 in 2014, 0.45 in 2015, 0.47 in 2016, 0.59 in 2017 and 0.33 in 2018).

The demographic characteristics of the patients are summarized in Table 1. The mean age of patients was 57.6 ± 19.0 years and 74.3% were male. Among 393 episodes, 148 episodes (37.7%) were from surgical ward, 167 episodes (42.5%) were from ICU and 78 episodes (19.8%) were from internal medicine ward, as shown in Figure 2.

C. albicans was isolated in 19.3% of cases in internal medical wards while in 41.2% and 38.9% of cases in surgery wards and ICU, respectively. In contrast, a higher proportion of *C. tropicalis* (34.7%) was found in internal medicine wards compared to that in surgery wards (21.6%) and ICUs (21.6%).

Underlying diseases and clinical features

The majority of patients with *Candida* BSI had at least one co-morbidity. 118 (30%) patients had solid tumors, 48 (12.2%) patients had hematological malignancies, 77 (19.6%) patients had diabetes mellitus, 124 (31.6%) patients had chronic cardiac disease, 52 (13.2%) patients had chronic pulmonary disease, 42 (10.7%) patients had chronic renal failure, 26 (6.6%) patients' skin barrier has been considered compromised, 244 (62.1%) patients had prior surgical intervention, 54 (13.7%) patients with corticosteroid use, 88 (22.4%) patients had prior antifungal agents use, 255 (64.9%) patients received antibiotic prior *Candida* BSI onset. 244 (72%) patients had at least two co-morbidities. No patient had human immunodeficiency virus (HIV) infection. Regarding the severity, 309 (78.6%) patients had fever, 180 (45.8%) patients received parenteral nutrition, 147 (37.4%) patients received mechanical ventilation, 49 (12.5%) patients received renal replacement therapy, and 42 (10.7%) patients had neutropenia. The clinical characteristics of patients, by *Candida* species are shown in Table 2.

Candida species and antifungal susceptibility testing

393 *Candida* species were isolated in total. 141 (35.9%) of *Candida* BSI were *C. albicans* and 252 (64.1%) were non-*albicans* *Candida*. In non-*albicans* *Candida* sepsis cases, 87 (22.1%) were caused by *C. parapsilosis*, 69 (17.6%) by *C. tropicalis*, 48 (12.2%) by *C. glabrata*, 20 (5.1%) by *C. guilliermondii*, 8 (2.0%) by *C. sake*, 5 (1.3%) by *C. krusei*, and 15 by other species (4 *C. gum*, 3 *C. lusitaniae*, 2 *C. intermedia*, 2 *C. theae*, 2 *C. lipolytica*, 1 *C. famata* and 1 *C. haemulonii*).

Among 393 *Candida* species, there were 378 episodes with antifungal susceptibility testing results. According to CLSI breakpoints 2012 (CBPs), the rates of susceptibility of *C. albicans*, *C. parapsilosis*, *C. tropicalis* and *C. parapsilosis* to fluconazole and voriconazole were 94%, 89.5%, 52.2%, 0% and 93.3%, 91.9%, 61.2%, 95.8%, respectively. Their susceptibilities to itraconazole were worse (82.1%, 87.2%, 37.3%, 0%). Amphotericin B and 5-flucytosine remained superior to 95% susceptibility against common *Candida* spp., except for *C. krusei* and *C. guilliermondii*, which were only 20% and 47.4% susceptible to flucytosine, respectively (Table 4).

Antifungal therapy and outcome

Antifungal therapy was administered in 299 (76.1%) of the cases. 94 (23.9%) patients did not receive any antifungal treatment. Among the patients who received antifungal therapy, 247 (62.8%) received appropriate antifungal therapy, and 52 (13.2%) received delayed antifungal therapy (5 days after onset of *Candida* BSI). Fluconazole was most frequently used as empiric therapy, followed by echinocandins and voriconazole. 18 (4.6%) patients with *Candida* BSI received a combination therapy.

The overall, 30-day mortality rate was 28.5%. Mortality rate was significantly higher in internal medicine wards and in ICUs than in surgical wards (37.2% and 34.7% vs. 16.9%, respectively, $P < 0.001$) (Figure 3a). The mortality for those who received appropriate or delayed antifungal therapy was 25.5% or 23.1% ($P = 0.012$ or $P = 0.046$), as compared to 39.4% for those who hadn't receive any antifungal therapy. However, there was no significant difference between the mortalities for those who received appropriate antifungal therapy and for those who received delayed antifungal therapy (Figure 3a and 3b).

In univariate analysis, age, solid tumor, diabetes mellitus, chronic cardiac disease, chronic renal failure, skin disease, prior surgical intervention, mechanical ventilation, neutropenia, and antifungal therapy were associated with 30-day mortality. In multivariate Cox regression analysis, advanced age (HR=1.025; 95%CI, 1.013-1.037; $P < 0.001$), chronic renal failure (HR=2.018; 95%CI 1.234-3.299; $P = 0.005$), mechanical ventilation (HR=1.950; 95%CI 1.307-2.912; $P = 0.001$), neutropenia (HR=4.347; 95%CI 2.462-7.675; $P < 0.001$), were independent risk factors for 30-day mortality, while antifungal therapy (HR=0.570; 95%CI 0.382-0.849; $P = 0.006$) was independent protective factor for 30-day mortality (Table 3).

Discussion

Our study showed that in our Tertiary-care hospital in Shanghai, the incidence of *Candida* BSI has increased steadily in the past 11 years. Several studies have shown a substantial increase in the past 2 decades, which was similar to our study [1, 5, 15]. Intensive use of broad-spectrum antibiotics may be the main cause. Also, gradually worsening hospitalized patient profiles, underlying co-morbidities including malignancy, and high frequency of surgeries may be predisposing risk factors for increasing incidence.

C. albicans was still the foremost pathogen of *Candida* BSI. However, in recent years, the trend of increasing rates of non-*C. albicans* has been reported worldwide, which was also observed in our study (35.9% for *C. albicans* and 64.1% for non-*C. albicans*). *C. parapsilosis* (34.5%), *C. tropicalis* (27.4%) and *C. glabrata* (19.0%) account for most of non-*C. albicans* [16, 17]. In this study, the incidence of *C. guilliermondii* was incredibly higher than in other studies (4.8% vs. 0.4%) [18]. This could be related to the higher rate of parenteral nutrition and surgery (45.8% and 62.1%) in the current study, as some research implies that intravenous nutrition and surgery were significant risk factors for *Candida* BSI due to *C. guilliermondii*. [19].

The antifungal susceptibility testing showed that the susceptibility of *C. albicans*, *C. parapsilosis* and *C. sake* for fluconazole was quite high (94%, 89.5%, 100%), while resistance rate of *C. tropicalis* for fluconazole was as high as 43.3%, which was significantly higher than in other studies abroad [20, 21]. This may deserve more attention from clinicians in actual application.

There were 23.9% patients with *candida* BSI didn't receive any antifungal therapy in the present study. It was partly because some patients died before the results of fungal blood cultures can be obtained. Fluconazole was still the most frequently used empirical antifungal therapy, followed by echinocandins. The 30-day crude mortality rate was 28.5%; a statistically significant finding is that 30-day mortality rate for *Candida* BSI in patients from surgical wards was quite low compared with other wards. The contributing factor needs further study.

Another finding in our study was that there was no significant difference in 30-day mortality rate between the patients who received appropriate antifungal therapy and the patients who received delayed antifungal therapy (25.5% and 23.1%). So we further analyzed demographic data, underlying diseases and clinical features between these two groups, the result showed that there were no significant differences between two groups in age ($p = 0.33$), sex ($p = 0.89$), the number of underlying diseases ($p = 0.32$) and the number of severe clinical features ($p = 0.96$). The choice of antifungal agents between these two groups was further analyzed. In the appropriate antifungal therapy group, the rate of azoles use was 50.6%, and the rate of echinocandin use was 30.3%; while in the delayed antifungal therapy group, the rate of azoles use was 65.4%, and the rate of echinocandin use was 17.3%. The rate of echinocandin use was lower in the delayed antifungal therapy group than in the appropriate antifungal therapy group ($p = 0.038$). Is the lower rate of echinocandin use in the delayed antifungal therapy group one of the reasons that caused no significant difference in mortality between the two groups? Many studies have confirmed the important role of echinocandin in antifungal therapy. Echinocandin has been recommended as a first-line antifungal agent since 2009 [10]. Many reports also have shown its non-inferiority or superiority to fluconazole [22, 23]. Therefore, we believe that the lower rate of echinocandin use in the delayed antifungal treatment group is unlikely to lead to a decrease in 30-day mortality rate. Based on the above analysis, we think that the timing of antifungal treatment has no significant impact on the 30-day mortality rate. Many clinicians currently administrate empirical antifungal agents; our study result may have an impact on their traditional view. Overuse of antifungal drugs inevitably leads to waste of medical resources and rise of resistance. If taking empirical antifungal agents cannot improve mortality, we should take a second thought about it. There are several studies support our findings [7–9], they showed that severity of illness (APACHE-II Score) affected short-term survival

in patients with candida infection, whereas the choice of initial antifungal agents did not affect short-term survival. However, some studies had different opinions on the timing of antifungal agents use. Bassetti's research showed that the use of antifungal agents within 48 hours of obtaining a positive candida blood culture result is an independent protective factor for mortality during hospitalization[6]; Similarly, Tedeschi's research showed that the administration of appropriate antifungal agents within 72 hours after blood culture was a protective factor for mortality during hospitalization[24]. However, due to the single-centered and the retrospective natures of their studies, those results need to be confirmed by more studies. Despite that, our results have shown similar the risk factors (for example, age, neutropenia, mechanical ventilation, etc.) and protective factor (antifungal therapy) for 30-day mortality to theirs.

Although our data have been collected from a large hospital in Shanghai, our study has some limitations, with the most significant one being its retrospective nature. The severity of illness score (such as APACHE II score), timing of CVC removal was not included because of missing data. Secondly, our study was monocentric and the results may not be applicable to other settings.

Conclusion

Our retrospective study showed that the incidence of Candida BSI has increased in the past 11 years in Shanghai. Although the percentage of non- *C. albicans* has been increasing, the *C. albicans* remained the most frequently isolated species. The mortality of patients with Candida bloodstream infection was quite high, especially for those in internal medicine wards. Antifungal therapy did improve short-term survival of patients with candida BSI. Whether we should initiate preemptive antifungal therapy or apply antifungal therapy after antifungal susceptibility test need further discussion.

Declarations

Ethics approval and consent to participate: The study was approved by the local institutional review board (Ruijin Hospital, Shanghai Jiaotong University, School of medicine) and written patient consent was not required because of the observational nature of this study.

Consent for publication: Not applicable.

Availability of data and materials: All data generated or analysed during this study are included in this published article and its supplementary information files.

Competing interests: The authors declare that they have no competing interests.

Funding: This work was supported by Program for Outstanding Medical Academic Leader, National Nature Science Foundation of China [81772107,81772040], Scientific and Technological Innovation Act Program of Science and Technology Commission of Shanghai Municipality [18411950900], Key Discipline Construction Project of Shanghai Municipal Commission of Health and Family Planning [2016ZB0206], Clinical Research Innovation Project of Shanghai Hospital Development Center [SHDC12017116] and Program of Shanghai Jiao Tong University School of Medicine [DLY201803] to Er-Zhen Chen. This work was also supported by Program of Shanghai Municipal Commission of Health and Family Planning [201640089] to Zhi-Tao Yang.

Authors' contributions: ZTY, EZC and EQM made substantial contributions to conception and design. ZTY, YJZ, LW, TX LZ and XYL participated in acquisition of data. ZTY, YJZ and YC drafted the manuscript. ZTY and EZC revised it critically.

Acknowledgements: We thank Ms. Wen-Jing ZHENG to produce the massive time first to the article English grammar, the usage and so on has carried on the revision.

References

1. Bitar D, Lortholary O, Le Strat Y, Nicolau J, Coignard B, Tattévin P, Che D, Dromer F: **Population-based analysis of invasive fungal infections, France, 2001-2010.** *Emerging infectious diseases* 2014, **20**(7):1149-1155.
2. Jia X, Li C, Cao J, Wu X, Zhang L: **Clinical characteristics and predictors of mortality in patients with candidemia: a six-year retrospective study.** *European Journal of Clinical Microbiology & Infectious Diseases* 2018, **37**(9):1717-1724.
3. Marchetti O, Bille J, Fluckiger U, Eggimann P, Ruef C, Garbino J, Calandra T, Glauser M-P, Täuber MG, Pittet D *et al.*: **Epidemiology of Candidemia in Swiss Tertiary Care Hospitals: Secular Trends, 1991–2000.** *Clinical Infectious Diseases* 2004, **38**(3):311-320.
4. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB: **Nosocomial Bloodstream Infections in US Hospitals: Analysis of 24,179 Cases from a Prospective Nationwide Surveillance Study.** *Clinical Infectious Diseases* 2004, **39**(3):309-317.

5. Tiraboschi IN, Pozzi NC, Farias L, Garcia S, Fernandez NB: **[Epidemiology, species, antifungal resistance and outcome of candidemia in a university hospital in Buenos Aires, Argentina for 16 years]**. *Revista chilena de infectologia : organo oficial de la Sociedad Chilena de Infectologia* 2017, **34**(5):431-440.
6. Bassetti M, Molinari MP, Mussap M, Viscoli C, Righi E: **Candidaemia in internal medicine departments: the burden of a rising problem**. *Clinical Microbiology and Infection* 2013, **19**(6):E281-E284.
7. Parkins MD, Sabuda DM, Elsayed S, Laupland KB: **Adequacy of empirical antifungal therapy and effect on outcome among patients with invasive Candida species infections**. *Journal of Antimicrobial Chemotherapy* 2007, **60**(3):613-618.
8. Taur Y, Cohen N, Dubnow S, Paskovaty A, Seo SK: **Effect of antifungal therapy timing on mortality in cancer patients with candidemia**. *Antimicrobial agents and chemotherapy* 2010, **54**(1):184-190.
9. Grim SA, Berger K, Teng C, Gupta S, Layden JE, Janda WM, Clark NM: **Timing of susceptibility-based antifungal drug administration in patients with Candida bloodstream infection: correlation with outcomes**. *Journal of Antimicrobial Chemotherapy* 2011, **67**(3):707-714.
10. Pappas PG, Kauffman CA, Andes D, Benjamin DK, Jr., Calandra TF, Edwards JE, Jr., Filler SG, Fisher JF, Kullberg B-J, Zeichner LO *et al*: **Clinical Practice Guidelines for the Management Candidiasis: 2009 Update by the Infectious Diseases Society of America**. *Clinical Infectious Diseases* 2009, **48**(5):503-535.
11. Li F, Wu L, Cao B, Zhang Y, Li X, Liu Y: **Surveillance of the prevalence, antibiotic susceptibility, and genotypic characterization of invasive candidiasis in a teaching hospital in China between 2006 to 2011**. *BMC infectious diseases* 2013, **13**:353.
12. Zhang L, Wang H, Xiao M, Kudinha T, Mao LL, Zhao HR, Kong F, Xu YC: **The widely used ATB FUNGUS 3 automated readings in China and its misleading high MICs of Candida spp. to azoles: challenges for developing countries' clinical microbiology labs**. *PloS one* 2014, **9**(12):e114004.
13. Yang Z-T, Wu L, Liu X-Y, Zhou M, Li J, Wu J-Y, Cai Y, Mao E-Q, Chen E-Z, Lortholary O: **Epidemiology, species distribution and outcome of nosocomial Candida spp. bloodstream infection in Shanghai**. *BMC infectious diseases* 2014, **14**:241-241.
14. Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, Reboli AC, Schuster MG, Vazquez JA, Walsh TJ *et al*: **Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America**. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America* 2016, **62**(4):e1-50.
15. Ulu Kilic A, Alp E, Cevahir F, Ture Z, Yozgat N: **Epidemiology and cost implications of candidemia, a 6-year analysis from a developing country**. *Mycoses* 2017, **60**(3):198-203.
16. Chapman B, Slavin M, Marriott D, Halliday C, Kidd S, Arthur I, Bak N, Heath CH, Kennedy K, Morrissey CO *et al*: **Changing epidemiology of candidaemia in Australia**. *Journal of Antimicrobial Chemotherapy* 2016, **72**(4):1103-1108.
17. Sadeghi G, Ebrahimi-Rad M, Mousavi SF, Shams-Ghahfarokhi M, Razzaghi-Abyaneh M: **Emergence of non-Candida albicans species: Epidemiology, phylogeny and fluconazole susceptibility profile**. *Journal de Mycologie Médicale* 2018, **28**(1):51-58.
18. Pfaller MA, Andes DR, Diekema DJ, Horn DL, Reboli AC, Rotstein C, Franks B, Azie NE: **Epidemiology and outcomes of invasive candidiasis due to non-albicans species of Candida in 2,496 patients: data from the Prospective Antifungal Therapy (PATH) registry 2004-2008**. *PloS one* 2014, **9**(7):e101510.
19. Wu Z, Liu Y, Feng X, Liu Y, Wang S, Zhu X, Chen Q, Pan S: **Candidemia: incidence rates, type of species, and risk factors at a tertiary care academic hospital in China**. *Int J Infect Dis* 2014, **22**:4-8.
20. Maria S, Barnwal G, Kumar A, Mohan K, Vinod V, Varghese A, Biswas R: **Species distribution and antifungal susceptibility among clinical isolates of Candida parapsilosis complex from India**. *Revista Iberoamericana de Micología* 2018, **35**(3):147-150.
21. Neji S, Hadrich I, Trabelsi H, Abbes S, Cheikhrouhou F, Sellami H, Makni F, Ayadi A: **Virulence factors, antifungal susceptibility and molecular mechanisms of azole resistance among Candida parapsilosis complex isolates recovered from clinical specimens**. *Journal of biomedical science* 2017, **24**(1):67.
22. Lin K-Y, Chen P-Y, Chuang Y-C, Wang J-T, Sun H-Y, Sheng W-H, Chen Y-C, Chang S-C: **Effectiveness of echinocandins versus fluconazole for treatment of persistent candidemia: A time-dependent analysis**. *Journal of Infection* 2018, **77**(3):242-248.
23. Reboli AC, Rotstein C, Pappas PG, Chapman SW, Kett DH, Kumar D, Betts R, Wible M, Goldstein BP, Schranz J *et al*: **Anidulafungin versus Fluconazole for Invasive Candidiasis**. *New England Journal of Medicine* 2007, **356**(24):2472-2482.
24. Tedeschi S, Tumietto F, Giannella M, Bartoletti M, Cristini F, Cioni G, Ambretti S, Carretto E, Sambri V, Sarti M *et al*: **Epidemiology and outcome of candidemia in internal medicine wards: A regional study in Italy**. *European Journal of Internal Medicine* 2016, **34**:39-44.

Tables

Table 1. Demographic of patients with *candida* bloodstream infection and distribution of *Candida* species

	<i>C. albicans</i>	<i>C. Parapsilosis</i>	<i>C. Tropicalis</i>	<i>C. glabrata</i>	<i>C. guilliermondii</i>	<i>C. sake</i>	<i>C. krusei</i>	Other <i>Candida spp.</i>	Total
	(n=141)	(n=87)	(n=69)	(n=48)	(n=20)	(n=8)	(n=5)	(n=15)	(n=393)
Age (year)	65.2±14.5	53.2±20.3	50.5±19.5	60.7±17.5	50.5±19.4	52±20.6	40.8±27.1	52.6±20.0	57.6±19.0
Male(n,%)	102(73.4)	60(69.0)	51(73.9)	44(91.7)	14(70)	8(100)	2(40)	11(73.3)	292(74.3)
Origin(n,%)									
Internal medicine ward	15(10.6)	19(21.8)	27(39.1)	7(14.6)	3(15)	0(0)	3(60)	4(26.7)	78(19.8)
Surgical ward	61(43.3)	32(36.8)	16(23.2)	15(31.3)	10(50)	6(75)	0(0)	8(53.3)	148(37.7)
ICU	65(46.1)	36(41.4)	26(37.7)	26(54.1)	7(35)	2(25)	2(40)	3(20)	167(42.5)
Time from admission to infection (d)	30.6±35.3	48.4±56.2	37.7±32.4	27.5±19.1	35.9±52.5	120.6±242.7	64.2±68.6	21.5±13.6	37.6±53.1
Length of hospital stay (d)	56.0±54.9	83.2±78.1	71.5±56.1	67.1±72.7	97.7±142.6	178.5±281.7	92.4±88.5	52.7±101.5	71.1±82.8
Turnaround Time (d)	4.3±1.9	4.5±1.1	3.8±1.1	4.8±1.3	4.3±1.2	4.5±1.6	4.4±1.5	5.9±1.8	4.4±1.5

Other *Candida spp.* Includes *C. guii*4 cases, *C. lusitaniae*3 cases, *C. intermedia*2 cases, *C. lipolytica* (2cases), *C. theae*2 cases, *C.famata*1case and *C. haemulonii*1 case.

Abbreviation: ICU, intensive care unit

Table2. Underlying disease and clinical feature of *Candida* bloodstream infection (n,%)

	<i>C. albicans</i>	<i>C. Parapsilosis</i>	<i>C. Tropicalis</i>	<i>C. glabrata</i>	<i>C. guilliermondii</i>	<i>C. sake</i>	<i>C. krusei</i>	Other <i>Candida spp.</i>	Total
	(n=141)	(n=87)	(n=69)	(n=48)	(n=20)	(n=8)	(n=5)	(n=15)	(n=393)
Underlying disease									
Solid tumor	47(33.3)	26(29.9)	13(18.8)	17(35.4)	6(30)	2(25)	0(0)	7(46.7)	118(30)
Hematologic malignancy	8(5.7)	6(6.9)	24(34.8)	2(4.2)	2(10)	1(12.5)	3(60)	2(13.3)	48(12.2)
Diabetes mellitus	33(23.4)	21(24.1)	8(11.6)	9(18.8)	1(5)	1(12.5)	0(0)	4(26.7)	77(19.6)
Chronic cardiac disease	55(39)	22(25.3)	16(23.2)	18(37.5)	6(30)	3(37.5)	2(40)	2(13.3)	124(31.6)
Chronic pulmonary disease	26(18.4)	9(10.3)	5(7.2)	6(12.5)	1(5)	1(12.5)	1(20)	3(20)	52(13.2)
Chronic renal failure	18(12.8)	6(6.9)	6(8.7)	5(10.4)	5(25)	0(0)	0(0)	2(13.3)	42(10.7)
Skin barrier compromised	5(3.5)	9(10.3)	5(7.2)	1(2.1)	3(15)	3(37.5)	0(0)	0(0)	26(6.6)
Prior surgical intervention (<1 month)	97(68.8)	48(55.2)	36(52.2)	30(62.5)	15(75)	6(75)	2(40)	10(66.7)	244(62.1)
Corticosteroid use	11(7.8)	13(14.9)	12(17.4)	9(18.8)	4(20)	0(0)	3(60)	2(13.3)	54(13.7)
Prior use of antifungal agents (<6 months)	20(14.2)	19(21.8)	24(34.8)	11(22.9)	8(40)	1(12.5)	4(80)	1(6.7)	88(22.4)
Severity of clinical feature									
Fever (T>38.2°C)	114(80.9)	63(72.4)	60(87)	34(70.8)	16(80)	6(75)	3(60)	13(86.7)	309(78.6)
Parenteral nutrition	71(50.4)	42(48.3)	28(40.6)	23(47.9)	5(25)	3(37.5)	2(40)	6(40)	180(45.8)
Mechanical ventilation	58(41.1)	31(35.6)	23(33.3)	25(52.1)	5(25)	2(25)	2(40)	1(6.7)	147(37.4)
Renal replacement therapy	17(12.1)	10(11.5)	9(13)	7(14.6)	5(25)	0(0)	1(20)	0(0)	49(12.5)
Central venous catheter	121(85.8)	67(77)	49(71)	43(89.6)	17(85)	5(62.5)	4(80)	10(66.7)	316(80.4)
Neutropenia	4(2.8)	8(9.2)	22(31.9)	1(2.1)	2(10)	0(0)	3(60)	2(13.3)	42(10.7)
28-day mortality	54(38.3)	16(18.4)	19(27.5)	13(27.1)	3(15)	1(12.5)	1(20)	5(33.3)	112(28.5)

Other *Candida spp.* includes *C. gum* (4 cases), *C. lusitanae* (3 cases), *C. intermedia* (2 cases), *C. lipolytica* (2cases) , *C. theae* (2 cases), *C. famata* (1 case) and *C. haemulonii* (1 case)

Table 3. Multivariate Cox regression analysis for the risk factors about 28-day mortality of <i>candida</i> bloodstream infection (393 episodes)					
28-day outcome	Multivariate analysis				
	Survival (n=281)	Death (n=112)	P value	HR (95%CI)	P value
Gender, male [n (%)]	216(76.9)	76(67.9)	0.065	-	-
Age (years, Mean±SD)	55.2±19.5	63.6±16.2	<0.01	1.025(1.013-1.037)	<0.001
Underlying disease				-	-
Solid tumor [n (%)]	91(32.4)	27(24.1)	0.106	-	-
Hematologic malignancy [n (%)]	32(11.4)	16(14.3)	0.428	-	-
Diabetes mellitus [n (%)]	49(17.4)	28(25)	0.088	-	-
Chronic Cardiac disease [n (%)]	72(25.6)	52(46.4)	<0.01	-	0.105
Chronic Pulmonary disease [n (%)]	34(12.1)	18(16.1)	0.294	-	-
Chronic renal failure [n (%)]	20(7.1)	22(19.6)	<0.01	2.018(1.234-3.299)	0.005
Skin barrier compromised [n (%)]	24(8.5)	2(1.8)	0.015	-	0.308
Prior surgical intervention (<1month) [n (%)]	182(64.8)	62(55.4)	0.083	-	-
Corticosteroid use [n (%)]	40(14.2)	14(12.5)	0.652	-	-
Prior antifungal agents use (<6month)[n (%)]	64(22.8)	24(21.4)	0.772	-	-
Severity of clinical feature				-	-
Fever (T>38.2°C) [n (%)]	220(78.3)	89(79.5)	0.798	-	-
Parenteral nutrition [n (%)]	124(44.1)	56(50)	0.292	-	-
Mechanical ventilation [n (%)]	89(31.7)	58(51.8)	<0.01	1.950(1.307-2.912)	0.001
Renal replacement therapy [n (%)]	32(11.4)	17(15.2)	0.305	-	-
Central venous catheter [n (%)]	227(80.8)	89(79.5)	0.766	-	-
Neutropenia [n (%)]	24(8.5)	18(16.1)	0.029	4.347(2.462-7.675)	<0.001
Antifungal therapy	224(74.9)	75(25.1)	0.007	0.502(0.294-0.857)	0.006
No treatment	57(60.6)	37(39.4)			

Table 4. Antifungal susceptibility testing results (ATB Fungus 3) of 378 Candida(n,%)

	<i>C.albicans</i> (n=134)	<i>C.parapsilosis</i> (n=86)	<i>C.tropicalis</i> (n=67)	<i>C.glabrata</i> (n=47)	<i>C.krusei</i> (n=5)	<i>C.sake</i> (n=8)	<i>C.guilliermondii</i> (n=19)	Other <i>Candida</i> <i>spp.</i> (n=12)	Total n=378
Fluconazole									
S	126 (94)	77(89.5)	35 (52.2)	0 (0)	0 (0)	8(100)	13 (68.4)	9 (75.0)	268 70.9
SDD	1 (0.8)	6 (7.0)	3 (4.5)	44(93.6)	0 (0)	0 (0)	0 (0)	0 (0)	54 14.3
R	7 (5.2)	3 (3.5)	29 (43.3)	3 (6.4)	5 (100)	0 (0)	6 (31.6)	3 (25.0)	56 14.8
Itraconazole									
S	110 (82.1)	75 (87.2)	25 (37.3)	0 (0)	0 (0)	8 (100)	6 (31.6)	9 (75.0)	233 61.6
SDD	6 (4.5)	7 (8.1)	4 (6.0)	40 (85.1)	2 (40.0)	0 (0)	7 (36.8)	0 (0)	66 17.5
R	18 (13.4)	4 4.7	38 (56.7)	7 (14.9)	3 (60.0)	0 (0)	6 (31.6)	3 (25.0)	79 20.9
Voriconazole									
S	125 (93.3)	79 (91.9)	41 (61.2)	45 (95.8)	4 (80.0)	8 (100)	12 (63.2)	11 (91.7)	325 86.0
SDD	0 (0)	2 (2.3)	2 (3.0)	1 (2.1)	1 (2.0)	0 (0)	3 (15.8)	0 (0)	92.4
R	9 (6.7)	5 (5.8)	24 (35.8)	1 (2.1)	0 (0)	0 (0)	4 (21.0)	1 (8.3)	44 11.6
Amphotericin B									
S	133 (99.3)	83 (96.5)	67 (100)	47 (100)	5 (100)	8 (100)	18 (94.7)	11 (91.7)	372 98.4
R	1 (0.7)	3 (3.5)	0 (0)	0 (0)	0 (0)	0 (0)	1 (5.3)	1 (8.3)	61.6
Flucytosin									
S	132 (98.5)	85 (98.8)	65 (97.0)	46 (97.9)	1 (20.0)	8 (100)	9 (47.4)	12 (100)	358 94.7
R	2 (1.5)	1 (1.2)	2 (3.0)	1 (2.1)	4 (80.0)	0 (0)	10 (52.6)	0 (0)	205.3

15 *Candida spp.* isolats did not have susceptibility test, *C. albicans* (7), *C. parapsilosis* (2), *C. tropicalis* (2), and *glabrata, theae, gum,haemulonii* each.

Figures

Figure 1

Fig2. Distribution of *Candida* spp.

Figure 2

Figure 3